Levy HB, Chirigos M, Talmage J, McFarlin DE, Bever CT, Salazar A, Engel WK:  Studies with Poly IC:LC:  Effect of immune modulation and paralytic neurological diseases.  Proceedings of the International Symposium on Interferons, Ed. T. Kishida, Japan Convention Services, Osaka, Japan, 1984, pages 330-337.

 

Bever CT, Whitaker JN:  Proteinases in inflammatory demyelinating disease.  Springer Seminars in Immunopathology 8:  235-250, 1985.

 

Levy HB, Bever CT:  Immune modulating effects of Poly IC:LC in mice, monkeys, and men.  In Applied Bioactive Polymeric Systems, Editors Gebelein CG, Carraher CE, Plenum Press, New York, 1988, pages 205-222.

 

Panitch HS, Bever CT:  Clinical use of interferons in multiple sclerosis.  In Interferon:  Principles and Medical Applications, Editors Baron S, et al., The University of Texas Medical Branch at Galveston, Galveston, Texas, 1992.

 

Bever CT:  Current status of studies of aminopyridines in multiple sclerosis.  Annals of Neurology, 36 (Supplement): S118-S121, 1994.

 

Bever CT:  4-Aminopyridine:  Use in Multiple Sclerosis.  CNS Drug Reviews 1: 261-279, 1995.

 

Bever CT:  Aminopyridines.  In Handbook of Multiple Sclerosis, Second Edition, Ed. S Cook, Marcel Dekker, 1996.

 

Bever CT:  Symptomatic Treatment of Multiple Sclerosis, Current Treatment Options in Neurology, 1: 221-237, 1999.

 

Bever CT: Clinical Pharmacology of Abnormal Potassium Channel Organization in Demyelinated Axons, In Multiple Sclerosis as a Neuronal Disease, Ed. S.Waxman, Elsevier, 2005.

 

Judge SIV & Bever CT, Jr.  Potassium channel blockers in multiple sclerosis: Central nervous system Kv channels and effects of symptomatic treatment.  Pharmacology & Therapeutics 111:224-259, 2006.

 

 

Bever, CT:  Investigator Training:  Rating Neurological Impairment Using the Kurtzke Expanded Disability Status Scale.  University of Maryland, Baltimore, 1996.

 

Bever CT:  Quantitation of Neurological Impairment Using the Scripps Neurological Rating Scale and the Kurtzke Expanded Disability Status Scale.  University of Maryland, Baltimore, 1997.

 

Haselkorn J, Bourdette D, Bowen J, Bever CT: Multiple Sclerosis: Use of Disease Modifying Therapies. Employee Education System, Department of Veterans Affairs, Salt Lake City, UT

 

Book Review
 
Bever CT: Wolff's headache and other head pain, Journal of Nervous and Mental Disease, 177: 60, 1989

Journal Articles (Refereed)
 
Bever CT, Koenigsberger RM, Antunes JL, Wolff JA: Epidural metastasis in Wilm's tumor. American Journal of Diseases of Children 135: 644-646, 1981.
 
Taylor DW, Bever CT, Rollwagen FM, Evans CB, Asofsky R: The rodent malaria Plasmodium Yoelii lacks both types 1 and 2 T-independent antigens. Journal of Immunology 128: 1854-1082, 1982.
 
Bever CT, Chang HW, Penn AS, Jaffe IA, Bock E: Effects of penicillamine on acetylcholine receptor: Implications for penicillamine induced myasthenia gravis.  Neurology 32: 1077-1082, 1982.
 
Miller JR, Burke AM, Bever CT: Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. Annals of Neurology 13: 53-58, 1982.
 
Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP: The prognosis of ocular myasthenia. Annals of Neurology 14: 516-519, 1983.
 
Bever CT, Dretchen KL, Blake GJ, Chang HW, Penn AS, and Asofsky: Augmented antiacetylcholine receptor response following chronic penicillamine administration. Annals of Neurology 16: 9 - 13, 1984
 
Eldrich R, Anayotis CP, Schlesinger S, Cowen D, Bever CT, Patronas N, McFarland HF: Hereditary adult onset leukodystrophy simulating chronic progressive multiple sclerosis. New England Journal of Medicine 311: 948-953, 1984.
 
Bever CT, McFarlin DE, Levy HB: A comparison of interferon responses in males and females. Journal of Interferon Research 5: 423-428, 1985.
 
Bever CT, Salazar AM, Neeley E, Ferraraccio BF, Rose JW, McFarland HF, Levy HB, McFarlin DE: Preliminary trial of Poly IC:LC in chronic progressive multiple sclerosis. Neurology 36: 494-498, 1986.
 
Bever CT, McFarland HF, Levy HB, McFarlin DE: Cortisol induction by Poly IC:LC: Implications for clinical trials of interferon. Annals of Neurology 23: 196-199, 1988.
 
Bever CT, McFarland HF, McFarlin DE, Levy HB: The kinetics of interferon induction by Poly IC:LC in humans. Jounal of Interferon Research 8: 419-426, 1988.
 
Bever CT, Morgan KD, Whitaker JN: Cathepsin D activity in human peripheral blood mononuclear leukocytes. Inflammation 13: 309-316, 1989.
 
Bever CT, Snyder DS, Endres RO, Morgan KD, Postlethwaite A, Whitaker JN: Activation of astrocytic lysosomal proteinases by factors released by mononuclear leukocytes. Neurochemical Research 14: 37-41, 1989.
 
Leslie J, Bever CT: Analysis of 3,4 diaminopyridine in human serum by solid phase extraction and high performance liquid chromatography with ultraviolet detection, Journal of Chromatography 496: 214-222, 1989.
 
Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP: Preliminary trial of 3,4 diaminopyridine in multiple sclerosis patients. Annals of Neurology 27: 421-427, 1990.
 
Bever CT, Swoveland P: Astrocytosis and cathepsin D activity in experimental measles encepalomyelitis. Neurochemical Research 15: 667-671, 1990.
 
Bever CT, Panitch HS, Levy HB, McFarlin DE, Johnson KP: Gamma interferon induction in patients with chronic progressive multiple sclerosis. Neurololgy, 41: 1124-1127, 1991.
 
Ehrlich GD, Glaser JB, Mease J, Bryz-Gornia V, Waldmann, TA, Poisesz BJ, Greenberg SJ, and the HTLV-1 Working Group (CT Bever, member): Multiple sclerosis, retroviruses, and PCR. Neurology, 41: 335-343, 1991.
 
Bever CT, Jacobson S, Mingioli ES, McFarland HF, McFarlin DE, Levy HB: Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. International Journal of Immunopharmacology 13: 613-618, 1991.
 
Bever CT, and Asofsky R: Augmented IgG anti-acetylcholine receptor response following chronic penicillamine administration. Journal of Neuroimmunology 35: 131-137, 1992.
 
The IFNB Multiple Sclerosis Study Group (CT Bever, member). Interferon beta-1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661, 1993.
 
Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group (CT Bever, member). Interferon beta-1-¿ is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667, 1993.
 
Bever CT, Panitch HS, Johnson KP: Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology 44: 745-747, 1994.
 
Bever CT, Young D, Anderson PM, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, Fossler MJ, Devane J, Johnson KP. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized placebo-controlled, double-blind, concentration-controlled crossover trial. Neurology 44: 1054-1059, 1994.
 
Bever CT, Garver DW. Increased cathepsin B activity in mulitple sclerosis brain. Journal of the Neurological Sciences 131: 71-73, 1995.
 
The IFNB Multiple Sclerosis Study Group (CT Bever, member) and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1-b in the treatment of mulitple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277-1285, 1995.
 
Bever CT, Anderson PA, Smith GV, Panitch HS, Johnson KP. Isometric measurement of hamstrings and quadriceps strength in multiple sclerosis patients: Sensitivity and variability. Journal of Neurologic Rehabilitation, 9: 221-227, 1995.
 
Bever CT, Grattan L, Panitch HS, Johnson KP. The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Multiple Sclerosis 1: 165-169, 1995.
 
Khan OA, Xia Q, Bever CT, Johnson KP, Panitch HS, Dhib-Jalbut SS. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology, 46: 1639-1643, 1996.
 
Bever CT, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Hebel JR, Conway KL, Katz E, Johnson KP. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 47: 1457-1462, 1996.
 
Li Q, Bever CT. Gamma interferon induced increases in intracellular cathepsin B activity in PMA primed THP-1 cells are blocked by inhibitors of protein kinase C. Immunopharmacology and Immunotoxicology, 18: 375-396, 1996.
 
Li Q, Bever CT. Interferon-gamma induced increases in intracellular cathepsin B activity in THP-1 cells are dependent on RNA transcription. Journal of Neuroimmunology, 74: 77-84, 1997.
 
The IFNB Multiple Sclerosis Study Group (CT Bever, member) and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of mulitple sclerosis with interferon beta-1b. Neurology, 47: 889-894, 1996.
 
Li Q, Falkler WA, Bever CT. Endotoxin induces increased intracellular cathepsin B activity in THP-1 cells. Immunopharmacology and Immunotoxicology 19: 215-237, 1997.
 
Li Q, Bever CT. Regulation of cathepsin B activity by modulators of arachidonic acid metabolism in human monocytes. Oncology Reports 4: 1255-1260, 1997.
 
Li Q, Milo R, Panitch HS, Swoveland P, Bever CT. Effect of glatiramer acetate on interferon-b induced effector function in THP-1 cells. European J Pharmacology 342: 303-310, 1998.
 
Li Q, Milo R, Panitch H, Bever CT. Effect of propranolol and IFN-b on the induction of MHC class II expression and cytokine production by IFN-b in THP-1 human monocytic cells. Immunopharmacology and Immunotoxicology 20: 39-61, 1998.
 
Bever CT, Grattan L, Morris JG. Neurological symptoms following Pfeisterial exposure: case report and literature review. Maryland Medical Journal 47: 120-123, 1998.
 
Li Q, Bever CT. Modulation of interferon-b induced increases in cathepsin B in THP-1 cells by adrenergic agonists and antagonists. Cell Biology International 22: 13-20, 1998.
 
Mackowiak PA, Siegel E, Wasserman S, Cameron E, Nessaiver MS, Bever CT. Effects of interferon-beta on human cerebral blood flow distribution. Journal of Interferon and Cytokine Research 18: 393-397, 1998.
 
Li Q, Bever CT. Interferon-gamma induces cathepsin B expression in a human macrophage-like cell line by increasing both transcription and mRNA stability. International Journal of Molecular Medicine 2: 181-186, 1998.
 
Li Q, Bever CT. Effect of protein kinase modulators on the regulation of cathepsin B activity in THP-1 human monocytic leukemia cells. Oncology Reports 5: 227-233, 1998.
 
Friend KB, Grattan L, Bever CT, Rabin BM, Groninger L, Deluty RH. Language impairment in muliple sclerosis patients. The Clinical Neuropsychologist 13: 78-94, 1999.
 
Judge SIV, Monteiro MJ, Yeh JZ, Bever CT. Inactivation gating and 4-AP sensitivity in human brain Kv 1.4 potassium channel. Brain Research 831: 43-54, 1999.
 
Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC and the North American Linomide Investigators (CT Bever, member). Linomide in relapsing and secondary progressive MS, Part I: Trial design and clinical results. Neurology 54: 1726-1733, 2000.
 
Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC, the MRI Analysis Center of the University of Texas-Houston, Health Science Center and the North American Linomide Investigators (CT Bever, member). Linomide in relapsing and secondary progressive MS: Part II: MRI results. Neurology 54: 1734-1741, 2000.
 
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW and the CHAMPS Study Group (CT Bever, member) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, CHAMPS Study Group,. New England Journal of Medicine 343: 898-904, 2000.
 
Kappos L, Comi G, Panitch H, ...Bever C Jr, ...Liu XJ. Induction of a non-encephalogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Medicine 6: 1176-1182, 2000.
 
Li Q, Bever CT. Stimulation of RANTES chemokine secretion in human astroglial cells is dependent on De Novo transcription. Neurochemical Research, 26: 125-133, 2001.
 
Li Q, Bever CT. Glatiramer acetate blocks interleukin 1 dependent nuclear factor kappa B activation and RANTES expression in human U251MG astroglial cells. Molecular Brain Research 87: 48-60, 2001.
 
Li Q, Bever CT. Mechanisms underlying the synergistic effect of Th1 cytokines on RANTES chemokine production by human glial cells. International Journal of Molecular Medicine 7: 187-195, 2001.
 
Li QQ, Burt DR, Bever CT. Glatiramer acetate inhibition of tumor necrosis factor-alpha- induced RANTES expression and release from U-251 MG human astrocytic cells. J Neurochemistry , 77: 1-11, 2001.
 
Li QQ, Bever CT, Burt DR, Judge SIV, Trisler GD. Induction of RANTES chemokine expression in human astrocytic cells is dependent upon activation of NF-kappa-B transcription factor. International Journal of Molecular Medicine 7: 527-533, 2001.
 
Li QQ, Bever CT. Comparison of RANTES chemokine induction by Th1 cytokines in human astroglial cell lines. International Journal of Molecular Medicine 8: 95-101, 2001.
 
Judge SIV, Yeh JZ, Goolsby JE, Monteiro MJ, Bever CT, Jr.: Determinants of 4-Aminopyridine sensitivity in a human brain Kv1.4 K+ channel: Phenylalanine substitutions in leucine heptad repeat region stabilitze channel closed state. Molecular Pharmacology 61: 1-8, 2002
 
Cohen, J.A., Cutter, G.R., Fischer, J.S., Goodman, A.D., Heidenreich, F.R., Kooijmans, M.F., Sandrock, A.W., Rudick, R.A., Simon, J.H., Simonian, N.A., Tsao, E.C., Whitaker, J.N. for the IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59:679-687, 2002.
 
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, EVIDENCE Study Group (CT Bever, member) and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002 Nov 26;59(10):1496-506
 
Wolinsky, J.S., the PROMiSe Study Group (CT Bever, member). The diagnosis of primary progressive multiple sclerosis. Journal of the Neurological Sciences. 206:145-152, 2003.
 
Goolsby J, Marty MC, Helletz D, Chiappelli J, Tashko G, Yarnell D, Fishman P, Dhib-Jalbut S, Bever C, Pessac B, Trisler D. Haematopoietic progenitors express neural genes. Proc Natl Acad Sci U S A., 100: 14926-14931, 2003.
 
Graber J, Zhan M, Ford D, Kursch F, Francis G, Bever C, Panitch H, Calabresi P, Dhib-Jalbut S. Interferon-beta-1a induces increases in vascular cell adhesion molecules: implications for its mode of action in multiple sclerosis. J Neuroimmunology, In press.
 
Sullivan CL, Wilkens JA, Rabin BM, Demorest M, Bever C. Psychosocial adjustment to multiple sclerosis. Int J MS Care 6: 98-105, 2004
 
Sandberg-Wollheim M, Bever C, Carter J, Farkkila M, Hurwitz B, Lapierre Y, Chang P, Francis GS. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol 252: 8-13, 2005.
 
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE Study Group (CT Bever, Member); University of British Columbia MS/MRI Research Group. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005 May;62(5):785-92
 
Judge SIV, Bever CT, Lee JM, Hoffman PM. Voltage gated potassium channels in CNS inflammation and degeneration: New implications for MS, Journal of Rehabilitation Research and Development, 2005, In press.
 
Finley MA, Fasoli SE, Dipietro L, Ohloff J, MacClellan LR, Whitall J, Macko R, Bever CT Jr, Krebs HI, Hogan N. Short-duration robotic therapy in stroke patients with severe upper-limb motor impairment. Journal of Rehabilitation Research and Development, 2005, 42: 683-692.
 
McClellan LR, Bradham DD, Whitall J, Volpe BT, Wilson PD, Ohlhoff J, Meister C, Hogan N, Krebs HI, Bever CT. Robotic upper extremity neuro-rehabilitation in chronic stroke patients. Journal of Rehabilitation Research and Development, 2005, 42: 717-722.
 
Dipietro L, Krebs HI, Fasoli SE, Volpe BT, Stein J, Bever CT, Hogan N. Changing motor synergies in chronic stroke. J Neurophysiol 2007; 98: 757-768.